Financial assistance may be available to help you with the cost of Elevidys. your treatment plan your insurance coverage the cost of the visit to your healthcare professional to receive doses of ...

Genetic medicine firm Sarepta Therapeutics announced the tragic death of a young man with Duchenne muscular dystrophy (DMD) ...

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne ...

Additionally, regulatory bodies may require more stringent safety monitoring or impose restrictions on Elevidys’ use, which could increase costs and complexity for both Sarepta and healthcare ...

Additionally, regulatory bodies may require more stringent safety monitoring or impose restrictions on Elevidys’ use, which could increase costs and complexity for both Sarepta and healthcare ...

With revenues climbing steadily since 2022, Sarepta is just beginning to reap the benefits of Elevidys’ commercialization. In its most recent quarter, SRPT’s cost of sales was $132.3 million, while ...

Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...

Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare condition that causes muscle weakness ...